These data were corroborated by lower level of PD-1-positive CD8+ T cells in tumours treated with APR-246, as demonstrated by immunohistochemical staining of CD8+ cells with anti-PD-1 antibody (Fig. 6e and Fig. S5e, f). This evidence concerns the gene CD8A and neoplasm.